The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Open accessAbstract
Underneath the intricacy of every cancer lies mysterious events that impel the tumour cell and its posterity into abnormal growth and tissue invasion. Oncogenic mutations disturb the regulatory circuits responsible for the governance of versatile cellular functions, permitting tumour cells to endure deregulated proliferation, resist to proapoptotic insults, invade and erode normal tissues and above all escape apoptosis. This disruption of apoptosis has been highly implicated in various malignancies and has been exploited as an anticancer strategy. Owing to the fact that apoptosis causes minimal inflammation and damage to the tissue, apoptotic cell death-based therapy has been the centre of attraction for the development of anticancer drugs. Increased understanding of the molecular pathways underlying apoptosis has enabled scientists to establish unique approaches targeting apoptosis pathways in cancer therapeutics. In this review, we reconnoitre the two major pathways (intrinsic and extrinsic) targeted cancer therapeutics, steering toward chief modulators of these pathways, such as B-cell lymphoma 2 protein family members (pro- and antiapoptotic), inhibitor of apoptosis proteins, and the foremost thespian of extrinsic pathway regulator, tumour necrosis factor-related apoptosis-inducing agent. Together, we also will have a look from clinical perspective to address the agents (drugs) and therapeutic strategies adopted to target these specific proteins/pathways that have entered clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedThe Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
Kluck, R. M., Bossy-Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,714
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Zou, H., Henzel, W. J., Liu, X., Lutschg, A., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80501-2 · Cited by 3,145
Mitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,184
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
THE MITOCHONDRIAL DEATH/LIFE REGULATOR IN APOPTOSIS AND NECROSIS
Kroemer, G., Dallaporta, B., & Resche-Rigon, M. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.619 · Cited by 1,963
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Deveraux, Q. L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2215 · Cited by 1,388
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Certo, M., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., & Letai, A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,288
Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,233
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Hotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0901217 · Cited by 1,154
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,125
bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship
Strasser, A., Harris, A. W., & Cory, S. (1991) · Cell · doi:10.1016/0092-8674(91)90362-3 · Cited by 1,054
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
The mitochondrion in apoptosis: how Pandora's box opens
Zamzami, N., & Kroemer, G. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048073 · Cited by 1,028
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 948
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies
Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1499 · Cited by 874
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800
Ways of dying: multiple pathways to apoptosis
Adams, J. M. (2003) · Genes & Development · doi:10.1101/gad.1126903 · Cited by 776
An evolutionary perspective on apoptosis
Vaux, D. L., Haecker, G., & Strasser, A. (1994) · Cell · doi:10.1016/0092-8674(94)90350-6 · Cited by 756
Life in the balance: how BH3-only proteins induce apoptosis
Willis, S. N., & Adams, J. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.10.001 · Cited by 743
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
BAX activation is initiated at a novel interaction site
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Bcl-2-regulated apoptosis: mechanism and therapeutic potential
Adams, J. M., & Cory, S. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.05.004 · Cited by 658
Life and death in peripheral T cells
Krammer, P. H., Arnold, R., & Lavrik, I. N. (2007) · Nature Reviews Immunology · doi:10.1038/nri2115 · Cited by 653
The role of BH3-only proteins in the immune system
Strasser, A. (2005) · Nature Reviews Immunology · doi:10.1038/nri1568 · Cited by 621
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A. P., et al. (2000) · PubMed · Cited by 620
Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria
Llambi, F., Moldoveanu, T., Tait, S. W. G., Bouchier-Hayes, L., Temirov, J., McCormick, L. L., Dillon, C. P., & Green, D. R. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.001 · Cited by 596
Death receptor signal transducers: nodes of coordination in immune signaling networks
Wilson, N. S., Dixit, V., & Ashkenazi, A. (2009) · Nature Immunology · doi:10.1038/ni.1714 · Cited by 559
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
Myc-driven endogenous cell competition in the early mammalian embryo
Clavería, C., Giovinazzo, G., Sierra, R., & Torres, M. (2013) · Nature · doi:10.1038/nature12389 · Cited by 371
Targeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
Myeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 367
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
Zhou, P., Qian, L., Kozopas, K. M., & Craig, R. W. (1997) · Blood · doi:10.1182/blood.v89.2.630 · Cited by 326
Alternative cell death mechanisms in development and beyond
Yuan, J., & Kroemer, G. (2010) · Genes & Development · doi:10.1101/gad.1984410 · Cited by 290
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
Targeting the Bcl-2 family for cancer therapy
Thomas, S., Quinn, B. A., Das, S. K., Dash, R., Emdad, L., Dasgupta, S., Wang, X.-Y., Dent, P., Reed, J. C., Pellecchia, M., et al. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.733001 · Cited by 277
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
The Role of Environmental Carcinogens, Viruses, and Genetic
Powers, A., & Carbone, M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.4 · Cited by 274
O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S., Kipps, T., Keating, M. J., Viallet, J., & Cheson, B. D. (2009) · Blood · doi:10.1182/blood-2008-02-137943 · Cited by 274
Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263
α-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media
Bacon, T. A., Morvan, F., Rayner, B., Imbach, J.-L., & Wickstrom, E. (1988) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(88)90065-6 · Cited by 255
Regulation of hematopoietic and leukemic stem cells by the immune system
Riether, C., Schürch, C. M., & Ochsenbein, A. F. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.89 · Cited by 250
Pepper, C., Lin, T. T., Pratt, G., Hewamana, S., Brennan, P., Hiller, L., Hills, R., Ward, R., Starczynski, J., Austen, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-157131 · Cited by 248
Soria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Tolcher, A. W., Mita, A., Lewis, L. D., Garrett, C. R., Till, E., Daud, A. I., Patnaik, A., Papadopoulos, K., Takimoto, C., Bartels, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2064 · Cited by 238
Trials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
Oligodeoxynucleotide stability in subcellular extracts and culture media
Wickstrom, E. (1986) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(86)90021-7 · Cited by 233
Badros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J. J., Espinoza-Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231
BH3-only proteins and their roles in programmed cell death
Giam, M., Huang, D. C. S., & Bouillet, P. (2008) · Oncogene · doi:10.1038/onc.2009.50 · Cited by 229
Van Poznak, C., Seidman, A. D., Reidenberg, M. M., Moasser, M. M., Sklarin, N., Van Zee, K., Borgen, P., Gollub, M., Bacotti, D., Yao, T.-J., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010686204736 · Cited by 222
Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera
Akhtar, S., Kole, R., & Juliano, R. L. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90480-y · Cited by 214
Marcucci, G., Maharry, K., Whitman, S. P., Vukosavljevic, T., Paschka, P., Langer, C., Mrózek, K., Baldus, C. D., Carroll, A. J., Powell, B. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8720 · Cited by 192
Chi, K. N., Gleave, M. E., Klasa, R. J., Murray, N., Bryce, C. J., de Menezes, D. E. L., D’Aloisio, S., & Tolcher, A. W. (2001) · PubMed · Cited by 191
Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak
Lindqvist, L. M., Heinlein, M., Huang, D. C. S., & Vaux, D. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406425111 · Cited by 190
Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins
Mérino, D., Giam, M., Hughes, P. D., Siggs, O. M., Heger, K., O'Reilly, L. A., Adams, J. M., Strasser, A., Lee, E. F., Fairlie, W. D., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200905153 · Cited by 185
Liu, G., Kelly, W. K., Wilding, G., Leopold, L., Brill, K., & Somer, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2985 · Cited by 181
Cancer therapeutics: Targeting the apoptotic pathway
Khan, K. H., Blanco-Codesido, M., & Molife, L. R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.012 · Cited by 180
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
Targeting apoptotic and autophagic pathways for cancer therapeutics
Liu, J.-J., Lin, M., Yu, J.-Y., Liu, B., & Bao, J.-K. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.001 · Cited by 170
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
Labi, V, Erlacher, M., Kiessling, S., & Villunger, A. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401940 · Cited by 167
Rudin, C. M., Salgia, R., Wang, X., Hodgson, L. D., Masters, G. A., Green, M., & Vokes, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3461 · Cited by 166
Rudin, C. M., Kozloff, M., Hoffman, P. C., Edelman, M. J., Karnauskas, R., Tomek, R., Szeto, L., & Vokes, E. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.148 · Cited by 166
Tolcher, A. W., Chi, K., Kuhn, J., Gleave, M., Patnaik, A., Takimoto, C., Schwartz, G., Thompson, I., Berg, K., D'Aloisio, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2145 · Cited by 166
Пили, Р., Salumbides, B. C., Zhao, M., Altiok, S., Qian, D. Z., Zwiebel, J. A., Carducci, M. A., & Rudek, M. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.527 · Cited by 160
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M. M., Fox, N. L., Miceli, R. C., Ullrich, S. J., Fisher, G. A., & Tolcher, A. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp292 · Cited by 157
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0631 · Cited by 152
Qiu, T., Zhou, L. Q., Zhu, W., Wang, T., Wang, J., Shu, Y., & Liu, P. (2013) · Future Oncology · doi:10.2217/fon.12.173 · Cited by 152
Sonpavde, G., Matveev, V. B., Burke, J. M., Caton, J. R., Fleming, M. T., Hutson, T. E., Galsky, M. D., Berry, W. R., Karlov, P., Holmlund, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr555 · Cited by 149
Gautschi, O. P., Tschopp, S., Olie, R. A., Leech, S. H., Simões‐Wüst, A. P., Ziegler, A., Baumann, B., Odermatt, B. F., Hall, J., Stahel, R. A., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.463 · Cited by 145
Marcucci, G., Stock, W., Dai, G., Klisovic, R. B., Liu, S., Klisovic, M. I., Blum, W. G., Kefauver, C. A., Sher, D. A., Green, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.118 · Cited by 141
Histone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Venugopal, B., Baird, R. D., Kristeleit, R. S., Plummer, R., Cowan, R. A., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y. A., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 130
Ferreira, C. G., van der Valk, P., Span, S. W., Ludwig, I., Smit, E. F., Kruyt, F. A. E., Pinedo, H. M., van Tinteren, H., & Giaccone, G. (2001) · PubMed · Cited by 126
Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch, H. T., Boland, C. R., Rodríguez-Bigas, M. A., Amos, C. I., Lynch, J. F., & Lynch, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3119 · Cited by 124
Ellis, L., Bots, M. L., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P. W., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 123
Dong, M., Ning, Z., Xing, P.-Y., Xu, J.-L., Cao, H., Dou, G.-F., Meng, Z., Shi, Y., Lu, X., & Feng, F.-Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1847-5 · Cited by 122
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz, R. M., Patel, V. F., Worzalla, J. F., & Shih, C. (1999) · PubMed · Cited by 111
Rödel, F., Frey, B., Leitmann, W., Capalbo, G., Weiß, C., & Rödel, C. M. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.011 · Cited by 108
Ferreira, C. G., van der Valk, P., Span, S. W., Jonker, J. M., Postmus, P. E., Kruyt, F. A. E., & Giaccone, G. (2001) · Annals of Oncology · doi:10.1023/a:1011167113067 · Cited by 107
Systems biology of apoptosis signaling networks
Lavrik, I. N. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.07.001 · Cited by 101
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 101
Ramp, U., Krieg, T. M., Çalışkan, E., Mahotka, C., Ebert, T., Willers, R., Gabbert, H. E., & Gerharz, C. D. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.03.011 · Cited by 100
Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.005 · Cited by 100
IAP antagonists: promising candidates for cancer therapy
Mannhold, R., Fulda, S., & Carosati, E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.003 · Cited by 98
Mechanical aspects of apoptosome assembly
Shi, Y. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.09.006 · Cited by 98
Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
Dineen, S. P., Roland, C. L., Greer, R. M., Carbon, J. G., Toombs, J. E., Gupta, P. K., Bardeesy, N. M., Sun, H., Williams, N. S., Minna, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3892 · Cited by 98
Dean, E. J., Jodrell, D. I., Connolly, K., Danson, S. J., Jolivet, J., Durkin, J. P., Morris, S., Jowle, D., Ward, T. H., Cummings, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5677 · Cited by 95
Systems biology of death receptor networks: live and let die
Lavrik, I. N. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.160 · Cited by 93
Parikh, S. A., Kantarjian, H. M., Schimmer, A. D., Walsh, W., Asatiani, E., El‐Shami, K., Winton, E. F., & Verstovšek, S. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.059 · Cited by 89
Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
Yee, J., Sadar, M. D., Sin, D. D., Kuzyk, M. A., Xing, L., Kondra, J., McWilliams, A. M., Man, S. F. P., & Lam, S. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4233 · Cited by 79
Ravi, R. K., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H. E., Mayer, E.-G., Yu, H., Pardoll, D. M., Ashkenazi, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2488 · Cited by 78
Banerji, U., van Doorn, L., Papadatos-Pastos, D., Kristeleit, R. S., Debnam, P. M., Tall, M., Stewart, A., Raynaud, F. I., Garrett, M. D., Toal, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3165 · Cited by 77
Chanan-Khan, A. A., Niesvizky, R., Hohl, R. J., Zimmerman, T. M., Christiansen, N. P., Schiller, G. J., Callander, N. S., LISTER, J. W., Oken, M. M., & Jagannath, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902748971 · Cited by 75
Momparler, R. L., Côté, S., Momparler, L. F., & Idaghdour, Y. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-19 · Cited by 75
Kirschbaum, M. H., Foon, K. A., Frankel, P. H., Ruel, C., Pulone, B., Tuscano, J. M., & Newman, E. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.877134 · Cited by 74
Histone deacetylase inhibitors in cancer therapy. A review
Hraběta, J., Stiborová, M., Adam, V., Kizek, R., & Eckschlager, T. (2013) · Biomedical Papers · doi:10.5507/bp.2013.085 · Cited by 74
Dai, Y., Liu, M., Tang, W., Li, Y., Lian, J., Lawrence, T. S., & Xu, L. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-392 · Cited by 72
Liu, S. S., Tsang, B. K., Cheung, A., Xue, W. C., Cheng, D. K.-L., Ng, T. Y., Wong, L. C., & Ngan, H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00085-5 · Cited by 71
Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)
Herbst, R. S., & Frankel, S. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040018 · Cited by 70
Grishina, O., Schmoor, C., Döhner, K., Hackanson, B. W., Lubrich, B., May, A. M., Cieslik, C., Müller, M. J., & Lübbert, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1432-5 · Cited by 66
Polier, G., Giaisi, M., Köhler, R., Müller, W. W., Lutz, C., Buss, E. C., Krammer, P. H., & Li‐Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29009 · Cited by 62
Wroblewski, D., Mijatov, B., Mohana‐Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs330 · Cited by 60
Gray, J. E., Haura, E. B., Chiappori, A., Tanvetyanon, T., Williams, C. C., Pinder-Schenck, M. C., Kish, J. A., Kreahling, J. M., Lush, R. M., Neuger, A. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2235 · Cited by 60
Becher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60
Dai, Y., Liu, M., Tang, W., DeSano, J. T., Burstein, E., Davis, M. A., Pienta, K. J., Lawrence, T. S., & Xu, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0188 · Cited by 59
Golstein, P. (1998) · Science · doi:10.1126/science.281.5381.1283 · Cited by 54
Weber, D. M., Graef, T. T., Hussein, M. A., Sobecks, R. M., Schiller, G. J., Lupinacci, L. C., Hardwick, J. S., & Jagannath, S. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.07.007 · Cited by 51
Bauer, S., Hilger, R. A., Mühlenberg, T., Grabellus, F., Nagarajah, J., Hoiczyk, M., Reichardt, A., Ahrens, M., Reichardt, P., Grünewald, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.826 · Cited by 50
Zorzi, A. P., Bernstein, M. L., Samson, Y., Wall, D. A., Desai, S. J., Nicksy, D., Wainman, N., Eisenhauer, E. A., & Baruchel, S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24694 · Cited by 50
LoRusso, P. M., Hong, D. S., Heath, E. I., Kurzrock, R., Wang, D., Hsu, M. L., Goyal, L., Wiezorek, J. S., Storgard, C. M., & Herbst, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3534 · Cited by 50
Mathematical modeling of apoptosis
Schleich, K., & Lavrik, I. N. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-44 · Cited by 49
Camidge, D. R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1167 · Cited by 49
Understanding apoptosis by systems biology approaches
Lavrik, I. N., Eils, R., Fricker, N., Pforr, C., & Krammer, P. H. (2009) · Molecular BioSystems · doi:10.1039/b905129p · Cited by 48
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Brinkmann, K., & Kashkar, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.61 · Cited by 47
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., & Yamamoto, N. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9666-9 · Cited by 46
Apoptosis-inducing agents: a patent review (2010 – 2013)
Kamal, Ä., Faazil, S., & Malik, M. S. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.877445 · Cited by 46
Lheureux, S., N’Diaye, M., Blanc‐Fournier, C., Dugué, A. E., Clarisse, B., Dutoit, S., Giffard, F., Abeilard, E., Briand, M., Labiche, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29104 · Cited by 43
Grand challenges in cell death and survival: apoptosis vs. necroptosis
Walsh, C. M. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00003 · Cited by 43
Role of Myeloid Cell Factor-1 (Mcl-1) in Chronic Lymphocytic Leukemia
Johnston, J. B., Paul, J. T., Neufeld, N. J., Haney, N., Kropp, D. M., Hu, X., Cheang, M., & Gibson, S. B. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001723317 · Cited by 41
Özvaran, M. K., Cao, X. X., Miller, S. D., Monia, B. P., Hong, W. K., & Smythe, W. R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.545.3.5 · Cited by 40
The chains of death: A new view on caspase-8 activation at the DISC
Schleich, K., Krammer, P. H., & Lavrik, I. N. (2013) · Cell Cycle · doi:10.4161/cc.23464 · Cited by 39
Targeting the Bcl-2 Family in Cancer Therapy
Papadopoulos, K. P. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.008 · Cited by 39
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2013) · PubMed · Cited by 37
Berenson, J. R., Hilger, J. D., Yellin, O., Boccia, R. V., Matous, J., Dressler, K. P., Ghazal, H. H., Jamshed, S., Kingsley, E. C., Harb, W. A., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1910-2 · Cited by 36
Simões‐Wüst, A. P., Hopkins-Donaldson, S., Sigrist, B., Belyanskaya, L. L., Stahel, R. A., & Zangemeister‐Wittke, U. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.199 · Cited by 36
New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581945 · Cited by 35
Renault, T. T., Elkholi, R., Bharti, A., & Chipuk, J. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569632 · Cited by 34
Mao, H., Liu, P. S., Zheng, J. F., Zhang, P. H., Zhou, L., Xin, G., & Liu, C. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.010 · Cited by 33
Yee, L., Burris, H. A., Kozloff, M. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4129 · Cited by 31
Pacey, S., Plummer, R., Attard, G., Bale, C., Calvert, H., Blagden, S. P., Fox, N. L., Corey, A. E., & Bono, J. S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3055 · Cited by 23
Ryu, Y., Hall, C. P., Reynolds, C. P., & Kang, M. H. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538745 · Cited by 15
Lee, M., Ha, J., Yoon, H. S., Lee, C., & Chi, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.130 · Cited by 8
Bcl-2 Family and Their Therapeutic Potential
Liu, Q., Chi, X., Leber, B. F., & Andrews, D. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_4 · Cited by 7
Designer Proteins to Trigger Cell Death
Fairbrother, W. J., & Ashkenazi, A. (2014) · Cell · doi:10.1016/j.cell.2014.06.010 · Cited by 5
Vaux, D. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_6 · Cited by 4
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,658
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Mustafa, M., Ahmad, R., Tantry, I. Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin, Hassan, M. I., Habib, S., et al. (2024) · Cells · doi:10.3390/cells13221838 · Cited by 595
Fattori, V., Hohmann, M., Rossaneis, A., Pinho-Ribeiro, F., & Verri, W. (2016) · Molecules · doi:10.3390/molecules21070844 · Cited by 479
Metadata
- Authors
- Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T.
- Venue
- Cell Death & Disease
- Published
- 2016-01-14
- Volume
- 7
- Issue
- 1
- Pages
- e2058-e2058
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2233407520
- Cited by
- 279
- References
- 170
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.